Julie Priest

2PUBLICATIONS
0CO-AUTHORS
Patient safetyGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (2)

|Sep 03, 2024
Patient-Reported Outcomes After Switching to a 2-Drug Regimen of Fixed-Dose Combination Dolutegravir/Lamivudine: 48-Week Results from the SALSA Study.

Princy Kumar, Amanda E Clarke, Celia Jonsson-Oldenbüttel

|Aug 08, 2023
Comparing Real-World Healthcare Costs Associated with Single-Tablet Regimens for HIV-1: The 2-Drug Regimen Dolutegravir/Lamivudine vs. Standard 3- or 4-Drug Regimens.

Julie Priest, Guillaume Germain, François Laliberté

Pageof 1

Frequent Collaborators